EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Recent advances in targeted therapies and immunotherapies for triple-negative breast cancer

Gowhar Rashid, Deena Elsori, Zainab Naqvi, Tauqeer Zehra, Zeliha Selamoglu, Sadiya Mr, Anass M Abbas, Abubucker Peer Mohideen, Wael Hafez, Asaad Babker

Frontiers in Oncology · 28.09.2026 · 16

DOI: 10.3389/fonc.2026.1804620 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Oncology, online erschienen am 28.09.2026. Verfasst von Gowhar Rashid und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Biochemistry, SKIMS, Srinagar, Jammu and Kashmir, India. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 132 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This comprehensive review explores advancements in the treatment of Triple-Negative Breast Cancer (TNBC), emphasizing the transformative impact of targeted therapies and immunotherapies. Given TNBC’s aggressive nature and limited therapeutic options, this review provides an in-depth analysis of emerging strategies that aim to enhance patient outcomes. Within targeted therapies, we discuss molecular subtypes and evaluate the efficacy of PARP inhibitors, EGFR inhibitors, and PI3K inhibitors, integrating insights from clinical trials. The immunotherapy landscape is examined through immune checkpoint inhibitors, Chimeric Antigen Receptor (CAR) T-cell therapy, and novel vaccine-based approaches. Combination strategies are assessed, focusing on clinical efficacy, safety, and resistance mechanisms. Additionally, we highlight emerging therapeutic innovations, including bispecific antibodies, advanced drug delivery systems, and personalized medicine approaches. Beyond treatment modalities, the review addresses key challenges such as therapy resistance, biomarker-driven treatment selection, and the integration of Artificial Intelligence in TNBC management. Future directions emphasize ongoing clinical trials and evolving therapeutic paradigms aimed at improving survival and quality of life for TNBC patients. As the field progresses, a multidisciplinary approach integrating precision oncology, innovative therapeutics, and patient-centered care will be critical. In conclusion, this review encapsulates current breakthroughs and envisions a future where targeted and immune-based interventions redefine TNBC treatment, offering new hope for patients and clinicians alike.

Schlagwörter

Stichwörter der Autor:innen

immunotherapiesmolecular subtypespatient-centric advancestargeted therapiestriple-negative breast cancer

Autor:innen und Institutionen

  • Department of Clinical Biochemistry, SKIMS, Srinagar, Jammu and Kashmir, India.
  • Faculty of Resillience, Deans Office Rabdan Academy, Abu Dhabi, United Arab Emirates.
  • Center for Disease Mapping and Therapeutic Research, Era University, Lucknow, India.
  • Research Metabolic Unit, Era University, Lucknow, India.
  • Department of Medical Biology, Medicine Faculty, Nigde Omer Halisdemir University, Nigde, Türkiye.
  • Department of Biology, Western Caspian University, Baku, Azerbaijan.

Zitieren

APA

Rashid, G., Elsori, D., Naqvi, Z., Zehra, T., Selamoglu, Z., Mr, S., Abbas, A. M., Mohideen, A. P., Hafez, W., & Babker, A. (2026). Recent advances in targeted therapies and immunotherapies for triple-negative breast cancer. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1804620

Vancouver

Rashid G, Elsori D, Naqvi Z, Zehra T, Selamoglu Z, Mr S, et al. Recent advances in targeted therapies and immunotherapies for triple-negative breast cancer. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1804620

BibTeX
@article{Rashid2026,
  author = {Rashid, Gowhar and Elsori, Deena and Naqvi, Zainab and Zehra, Tauqeer and Selamoglu, Zeliha and Mr, Sadiya and Abbas, Anass M and Mohideen, Abubucker Peer and Hafez, Wael and Babker, Asaad},
  title = {Recent advances in targeted therapies and immunotherapies for triple-negative breast cancer},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1804620}
}
Kostenlos starten →